ArticleThe Canadian journal of cardiology2007
Missed opportunities for the secondary prevention of cardiovascular disease in Canada.
Article in The Canadian journal of cardiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- 2011 Canadian Hypertension Education Program recommendations: an annual update.Canadian family physician Medecin de famille canadien · 2011Guideline
- Treatment Inertia in Patients With Familial Hypercholesterolemia.Journal of the American Heart Association · 2021Article
- Article
- Evaluation of the quality of care of a multi-disciplinary Risk Factor Assessment and Management Programme for Hypertension (RAMP-HT).BMC family practice · 2015Article
- Development of an interprofessional program for cardiovascular prevention in primary care: A participatory research approach.SAGE open medicine · 2014Article
- Advancing knowledge translation in primary care.Canadian family physician Medecin de famille canadien · 2012Article
- Results of a national survey on OTC medicines, Part 2: Do pharmacists support switching prescription agents to over-the-counter status?Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPC · 2012Article
- Polypill: lights and shadows.Current hypertension reports · 2010Review
- 2010 Canadian Hypertension Education Program recommendations: An annual update.Canadian family physician Medecin de famille canadien · 2010Article
- Management of atherothrombotic risk factors in high-risk Canadian outpatients.The Canadian journal of cardiology · 2009Article
- Hypertension management in Canada: good news, but important challenges remain.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStrong evidence supports the use of antithrombotic agents (antiplatelets or oral anticoagulants), statins and angiotensin-converting enzyme inhibitors in patients with atherosclerotic cardiovascular disease; beta-blockers are additionally indicated in patients with coronary artery disease.
objectivesThe investigators sought to determine the extent to which guideline-recommended treatments and target goals are adopted in ambulatory patients with cardiovascular disease in Canada.
methodsTwo large, prospective, community-based registries (the Vascular Protection Registry and the Guideline Oriented Approach to Lipid Lowering Registry) enrolled 9809 outpatients with coronary artery disease, cerebrovascular disease, peripheral vascular disease or multiple cardiovascular risk factors from primary care settings in nine provinces across Canada between 2001 and 2004. This analysis focused primarily on patients with cardiovascular disease (n=6296).
resultsAt baseline, antithrombotics, statins and angiotensin-converting enzyme inhibitors were used in 92%, 80% and 57% of patients, respectively; beta-blockers were used in 59% of patients with coronary artery disease. The dosing of most drug therapies was suboptimal compared with guideline-recommended dosing derived from clinical trials. Treatment goals for cardiovascular risk factors were suboptimally attained: low-density lipoprotein cholesterol in 50% of patients, total to high-density lipoprotein cholesterol ratio in 51% of patients, systolic and diastolic blood pressure in 58% and 78% of patients, respectively, and waist circumference and body mass index in 45% and 19%, respectively.
conclusionsThese data suggest specific opportunities for improving the care of patients with cardiovascular disease in Canada. The focus must now shift from awareness of treatment gaps to implementation of effective solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.